| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Diseases | 18 | 2019 | 239 | 4.130 |
Why?
|
| Kidney Failure, Chronic | 30 | 2018 | 518 | 4.090 |
Why?
|
| Renal Dialysis | 18 | 2019 | 259 | 3.920 |
Why?
|
| Nephrology | 8 | 2015 | 34 | 2.840 |
Why?
|
| Mucoproteins | 10 | 2015 | 14 | 2.380 |
Why?
|
| Mucin-1 | 8 | 2019 | 10 | 2.220 |
Why?
|
| Mutation | 19 | 2018 | 466 | 1.870 |
Why?
|
| Serum Albumin | 7 | 2012 | 53 | 1.550 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 7 | 2018 | 10 | 1.460 |
Why?
|
| Kidney Transplantation | 8 | 2018 | 348 | 1.450 |
Why?
|
| Humans | 94 | 2019 | 29093 | 1.410 |
Why?
|
| Nephritis, Interstitial | 5 | 2018 | 9 | 1.400 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2018 | 836 | 1.300 |
Why?
|
| Gout | 6 | 2015 | 14 | 1.240 |
Why?
|
| Diabetic Nephropathies | 9 | 2019 | 195 | 1.220 |
Why?
|
| Male | 65 | 2019 | 17807 | 1.220 |
Why?
|
| Uric Acid | 6 | 2015 | 24 | 1.210 |
Why?
|
| Middle Aged | 41 | 2019 | 10829 | 1.160 |
Why?
|
| Hyperuricemia | 7 | 2015 | 12 | 1.160 |
Why?
|
| Anti-Bacterial Agents | 5 | 2013 | 285 | 1.160 |
Why?
|
| Catheters, Indwelling | 4 | 2014 | 40 | 1.070 |
Why?
|
| Sickle Cell Trait | 3 | 2017 | 12 | 1.070 |
Why?
|
| Kidney | 12 | 2019 | 485 | 1.030 |
Why?
|
| Renin | 3 | 2017 | 112 | 1.000 |
Why?
|
| Female | 56 | 2019 | 18164 | 1.000 |
Why?
|
| Bacteremia | 3 | 2011 | 53 | 0.980 |
Why?
|
| Renal Insufficiency, Chronic | 3 | 2018 | 268 | 0.980 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2019 | 59 | 0.930 |
Why?
|
| Water-Electrolyte Imbalance | 2 | 2013 | 4 | 0.900 |
Why?
|
| Diabetes Mellitus | 4 | 2010 | 366 | 0.880 |
Why?
|
| Adult | 26 | 2019 | 8420 | 0.810 |
Why?
|
| Thrombosis | 4 | 2019 | 60 | 0.800 |
Why?
|
| Catheterization, Central Venous | 3 | 2014 | 60 | 0.760 |
Why?
|
| Rare Diseases | 1 | 2019 | 20 | 0.710 |
Why?
|
| Kidney Diseases, Cystic | 3 | 2010 | 12 | 0.710 |
Why?
|
| Pancreatic Elastase | 1 | 2019 | 3 | 0.690 |
Why?
|
| Glomerular Filtration Rate | 9 | 2018 | 287 | 0.690 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2019 | 21 | 0.690 |
Why?
|
| Aged | 34 | 2019 | 9487 | 0.690 |
Why?
|
| Radial Artery | 1 | 2019 | 15 | 0.690 |
Why?
|
| Veins | 1 | 2019 | 29 | 0.680 |
Why?
|
| Minocycline | 2 | 2011 | 11 | 0.680 |
Why?
|
| Adenine Phosphoribosyltransferase | 1 | 2018 | 3 | 0.680 |
Why?
|
| Metabolism, Inborn Errors | 1 | 2018 | 3 | 0.680 |
Why?
|
| Vascular Patency | 1 | 2019 | 66 | 0.680 |
Why?
|
| Urolithiasis | 1 | 2018 | 7 | 0.670 |
Why?
|
| Peritoneal Dialysis | 4 | 2013 | 22 | 0.670 |
Why?
|
| Arteriovenous Shunt, Surgical | 1 | 2019 | 45 | 0.670 |
Why?
|
| Kidney Calculi | 1 | 2018 | 25 | 0.660 |
Why?
|
| Upper Extremity | 1 | 2019 | 52 | 0.660 |
Why?
|
| Water-Electrolyte Balance | 3 | 2013 | 14 | 0.660 |
Why?
|
| Referral and Consultation | 1 | 2019 | 113 | 0.650 |
Why?
|
| Emigration and Immigration | 1 | 2018 | 32 | 0.640 |
Why?
|
| Carrier Proteins | 1 | 2019 | 131 | 0.640 |
Why?
|
| Risk Factors | 19 | 2014 | 3531 | 0.630 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 2 | 0.610 |
Why?
|
| Urate Oxidase | 2 | 2015 | 2 | 0.610 |
Why?
|
| Nephritis, Hereditary | 1 | 2017 | 3 | 0.600 |
Why?
|
| Adolescent | 14 | 2018 | 3254 | 0.580 |
Why?
|
| Equipment Contamination | 2 | 2007 | 11 | 0.580 |
Why?
|
| Kidney Tubules | 2 | 2019 | 25 | 0.550 |
Why?
|
| Genetic Testing | 2 | 2019 | 90 | 0.540 |
Why?
|
| Gout Suppressants | 1 | 2015 | 4 | 0.530 |
Why?
|
| Cardiovascular Diseases | 9 | 2012 | 1013 | 0.520 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 65 | 0.520 |
Why?
|
| Hypertension | 8 | 2014 | 906 | 0.520 |
Why?
|
| Albuminuria | 6 | 2014 | 176 | 0.520 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2014 | 15 | 0.510 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 21 | 0.510 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 35 | 0.500 |
Why?
|
| Glomerulonephritis | 2 | 2013 | 21 | 0.480 |
Why?
|
| Nephrotic Syndrome | 2 | 2017 | 12 | 0.480 |
Why?
|
| Child | 11 | 2018 | 2219 | 0.470 |
Why?
|
| Peritoneal Fibrosis | 1 | 2013 | 1 | 0.460 |
Why?
|
| Hemodialysis Solutions | 1 | 2013 | 4 | 0.460 |
Why?
|
| Device Removal | 1 | 2013 | 31 | 0.450 |
Why?
|
| Arthritis, Infectious | 1 | 2013 | 21 | 0.450 |
Why?
|
| Siblings | 2 | 2013 | 24 | 0.440 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2012 | 2 | 0.430 |
Why?
|
| Hypophosphatemia | 1 | 2012 | 3 | 0.430 |
Why?
|
| Death, Sudden | 1 | 2012 | 8 | 0.430 |
Why?
|
| Renal Replacement Therapy | 1 | 2012 | 16 | 0.430 |
Why?
|
| Societies, Medical | 4 | 2013 | 149 | 0.420 |
Why?
|
| Diabetes Complications | 2 | 2010 | 171 | 0.420 |
Why?
|
| Knee Joint | 1 | 2013 | 129 | 0.420 |
Why?
|
| Risk Assessment | 10 | 2019 | 1305 | 0.420 |
Why?
|
| Hospitalization | 2 | 2012 | 417 | 0.410 |
Why?
|
| Vital Signs | 1 | 2011 | 7 | 0.410 |
Why?
|
| African Americans | 5 | 2011 | 1373 | 0.400 |
Why?
|
| Retrospective Studies | 9 | 2019 | 3111 | 0.400 |
Why?
|
| Calcium | 1 | 2013 | 296 | 0.400 |
Why?
|
| Acetates | 2 | 2008 | 15 | 0.400 |
Why?
|
| Polyamines | 2 | 2008 | 10 | 0.400 |
Why?
|
| Anemia | 5 | 2016 | 55 | 0.380 |
Why?
|
| Peripheral Vascular Diseases | 2 | 2010 | 35 | 0.380 |
Why?
|
| Coronary Disease | 4 | 2007 | 200 | 0.380 |
Why?
|
| Family Health | 1 | 2010 | 78 | 0.360 |
Why?
|
| Hyperglycemia | 1 | 2010 | 82 | 0.360 |
Why?
|
| Diabetic Retinopathy | 1 | 2010 | 64 | 0.350 |
Why?
|
| Pedigree | 6 | 2018 | 133 | 0.350 |
Why?
|
| European Continental Ancestry Group | 3 | 2011 | 1131 | 0.350 |
Why?
|
| Time Factors | 6 | 2019 | 2001 | 0.340 |
Why?
|
| Hyperphosphatemia | 1 | 2008 | 6 | 0.340 |
Why?
|
| Phosphates | 2 | 2012 | 25 | 0.340 |
Why?
|
| Chelating Agents | 1 | 2008 | 17 | 0.340 |
Why?
|
| Prospective Studies | 11 | 2019 | 2019 | 0.340 |
Why?
|
| Congresses as Topic | 3 | 2013 | 37 | 0.330 |
Why?
|
| Immunosuppressive Agents | 4 | 2018 | 167 | 0.320 |
Why?
|
| United States | 9 | 2019 | 3630 | 0.320 |
Why?
|
| Proteinuria | 1 | 2007 | 57 | 0.310 |
Why?
|
| Gene Deletion | 2 | 2004 | 64 | 0.310 |
Why?
|
| Catheterization | 1 | 2007 | 58 | 0.300 |
Why?
|
| Dialysis Solutions | 1 | 2007 | 3 | 0.300 |
Why?
|
| Creatinine | 8 | 2005 | 174 | 0.300 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 130 | 0.300 |
Why?
|
| Disease Progression | 7 | 2019 | 572 | 0.300 |
Why?
|
| Child, Preschool | 5 | 2018 | 1167 | 0.290 |
Why?
|
| Hyperparathyroidism, Secondary | 1 | 2005 | 1 | 0.270 |
Why?
|
| Parathyroidectomy | 1 | 2005 | 10 | 0.270 |
Why?
|
| Edetic Acid | 1 | 2005 | 8 | 0.270 |
Why?
|
| Antimetabolites | 2 | 2018 | 10 | 0.260 |
Why?
|
| Allopurinol | 2 | 2018 | 6 | 0.260 |
Why?
|
| North Carolina | 6 | 2019 | 1423 | 0.260 |
Why?
|
| Young Adult | 6 | 2016 | 2402 | 0.260 |
Why?
|
| Hemoglobin, Sickle | 2 | 2017 | 7 | 0.250 |
Why?
|
| Hospital Mortality | 2 | 2019 | 186 | 0.250 |
Why?
|
| Polycystic Kidney Diseases | 1 | 2004 | 4 | 0.250 |
Why?
|
| Carotid Artery Diseases | 1 | 2005 | 109 | 0.250 |
Why?
|
| Longitudinal Studies | 7 | 2013 | 720 | 0.250 |
Why?
|
| Calcinosis | 1 | 2005 | 143 | 0.250 |
Why?
|
| Cause of Death | 4 | 2019 | 220 | 0.250 |
Why?
|
| Cross-Sectional Studies | 8 | 2012 | 1356 | 0.250 |
Why?
|
| Kidney Medulla | 1 | 2004 | 29 | 0.250 |
Why?
|
| Treatment Outcome | 6 | 2019 | 3099 | 0.250 |
Why?
|
| Genes, Dominant | 4 | 2016 | 26 | 0.240 |
Why?
|
| Age Factors | 5 | 2014 | 1108 | 0.230 |
Why?
|
| Urine | 2 | 2019 | 59 | 0.220 |
Why?
|
| Double-Blind Method | 2 | 2019 | 501 | 0.220 |
Why?
|
| Kidney Function Tests | 3 | 2012 | 102 | 0.210 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 709 | 0.200 |
Why?
|
| Academic Medical Centers | 3 | 2011 | 150 | 0.200 |
Why?
|
| Antihypertensive Agents | 2 | 2014 | 339 | 0.200 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 139 | 0.190 |
Why?
|
| DNA Mutational Analysis | 3 | 2017 | 67 | 0.190 |
Why?
|
| Aged, 80 and over | 8 | 2014 | 3717 | 0.190 |
Why?
|
| Infant | 3 | 2018 | 969 | 0.190 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2011 | 1079 | 0.190 |
Why?
|
| Phenotype | 4 | 2016 | 629 | 0.190 |
Why?
|
| Renal Insufficiency | 3 | 2006 | 53 | 0.190 |
Why?
|
| Registries | 3 | 2019 | 278 | 0.180 |
Why?
|
| Molecular Motor Proteins | 2 | 2011 | 58 | 0.180 |
Why?
|
| Myosin Heavy Chains | 2 | 2011 | 86 | 0.180 |
Why?
|
| Vesicular Transport Proteins | 1 | 2019 | 10 | 0.180 |
Why?
|
| Heterozygote | 2 | 2016 | 52 | 0.180 |
Why?
|
| Lysosomes | 1 | 2019 | 10 | 0.180 |
Why?
|
| Hypothermia, Induced | 1 | 2019 | 16 | 0.180 |
Why?
|
| Benzamides | 1 | 2019 | 54 | 0.170 |
Why?
|
| Algorithms | 2 | 2014 | 462 | 0.170 |
Why?
|
| Antisocial Personality Disorder | 1 | 2018 | 2 | 0.170 |
Why?
|
| Impulsive Behavior | 1 | 2018 | 7 | 0.170 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 13 | 0.170 |
Why?
|
| Violence | 1 | 2018 | 14 | 0.170 |
Why?
|
| Purine-Pyrimidine Metabolism, Inborn Errors | 1 | 2018 | 1 | 0.170 |
Why?
|
| Ribose-Phosphate Pyrophosphokinase | 1 | 2018 | 1 | 0.170 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2018 | 7 | 0.170 |
Why?
|
| Administration, Topical | 1 | 2019 | 130 | 0.170 |
Why?
|
| Internet | 1 | 2019 | 156 | 0.160 |
Why?
|
| Maxillary Fractures | 1 | 2018 | 3 | 0.160 |
Why?
|
| Maxilla | 1 | 2018 | 9 | 0.160 |
Why?
|
| Maxillofacial Injuries | 1 | 2018 | 9 | 0.160 |
Why?
|
| Lupus Nephritis | 1 | 2018 | 30 | 0.160 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2018 | 18 | 0.160 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 40 | 0.160 |
Why?
|
| Cell Adhesion Molecules | 1 | 2017 | 45 | 0.160 |
Why?
|
| Office Visits | 1 | 2018 | 71 | 0.160 |
Why?
|
| Hematologic Tests | 1 | 2017 | 11 | 0.150 |
Why?
|
| Predictive Value of Tests | 8 | 2015 | 787 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 39 | 0.150 |
Why?
|
| Fanconi Syndrome | 1 | 2016 | 1 | 0.150 |
Why?
|
| Electron Transport Complex I | 1 | 2016 | 3 | 0.150 |
Why?
|
| Survival Analysis | 5 | 2019 | 440 | 0.140 |
Why?
|
| Mitochondrial Diseases | 1 | 2016 | 11 | 0.140 |
Why?
|
| Calcium Compounds | 2 | 2008 | 8 | 0.140 |
Why?
|
| Stem Cells | 1 | 2019 | 292 | 0.140 |
Why?
|
| Bone Neoplasms | 1 | 2018 | 104 | 0.140 |
Why?
|
| DNA | 1 | 2017 | 204 | 0.140 |
Why?
|
| Biopsy | 3 | 2017 | 241 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 9 | 0.140 |
Why?
|
| Incidence | 5 | 2018 | 1119 | 0.140 |
Why?
|
| Prevalence | 4 | 2014 | 896 | 0.140 |
Why?
|
| Blood Group Antigens | 2 | 2006 | 4 | 0.140 |
Why?
|
| Drug Combinations | 2 | 2007 | 86 | 0.140 |
Why?
|
| Cystatins | 2 | 2005 | 8 | 0.140 |
Why?
|
| Mass Spectrometry | 1 | 2016 | 99 | 0.140 |
Why?
|
| Animals | 7 | 2019 | 7297 | 0.140 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 67 | 0.140 |
Why?
|
| Heart Failure | 3 | 2019 | 568 | 0.140 |
Why?
|
| Drug Monitoring | 1 | 2015 | 24 | 0.130 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 85 | 0.130 |
Why?
|
| Mitochondria | 1 | 2016 | 174 | 0.130 |
Why?
|
| Propensity Score | 1 | 2014 | 34 | 0.130 |
Why?
|
| Systole | 1 | 2014 | 87 | 0.120 |
Why?
|
| Alleles | 3 | 2016 | 251 | 0.120 |
Why?
|
| Catheter-Related Infections | 1 | 2014 | 10 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2018 | 859 | 0.120 |
Why?
|
| Veterans | 1 | 2014 | 50 | 0.120 |
Why?
|
| Logistic Models | 3 | 2011 | 727 | 0.120 |
Why?
|
| Prognosis | 3 | 2018 | 1362 | 0.120 |
Why?
|
| Acidosis | 1 | 2013 | 16 | 0.120 |
Why?
|
| Cohort Studies | 7 | 2019 | 1687 | 0.120 |
Why?
|
| Minisatellite Repeats | 1 | 2013 | 8 | 0.110 |
Why?
|
| Vomiting | 1 | 2013 | 24 | 0.110 |
Why?
|
| Nausea | 1 | 2013 | 49 | 0.110 |
Why?
|
| Erythropoietin | 2 | 2003 | 29 | 0.110 |
Why?
|
| Quality of Life | 1 | 2018 | 816 | 0.110 |
Why?
|
| Postoperative Complications | 2 | 2017 | 670 | 0.110 |
Why?
|
| Magnesium | 1 | 2012 | 22 | 0.110 |
Why?
|
| Hemodialysis, Home | 1 | 2012 | 13 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 2 | 2016 | 24 | 0.100 |
Why?
|
| Coronary Artery Bypass | 1 | 2012 | 100 | 0.100 |
Why?
|
| Length of Stay | 1 | 2012 | 292 | 0.100 |
Why?
|
| Patient Admission | 1 | 2011 | 53 | 0.100 |
Why?
|
| Chronic Disease | 3 | 2016 | 369 | 0.100 |
Why?
|
| Apoptosis | 2 | 2019 | 337 | 0.100 |
Why?
|
| Hospital Rapid Response Team | 1 | 2010 | 5 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 293 | 0.090 |
Why?
|
| Patient Selection | 1 | 2012 | 257 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 519 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 196 | 0.090 |
Why?
|
| Diet, Protein-Restricted | 1 | 2010 | 2 | 0.090 |
Why?
|
| Safety Management | 1 | 2010 | 31 | 0.090 |
Why?
|
| Heart Arrest | 1 | 2010 | 39 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 61 | 0.090 |
Why?
|
| Apolipoproteins | 1 | 2011 | 196 | 0.090 |
Why?
|
| Lipoproteins, HDL | 1 | 2011 | 247 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2012 | 359 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 176 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2011 | 466 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 525 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 871 | 0.080 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2007 | 6 | 0.080 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2007 | 4 | 0.080 |
Why?
|
| Glomerulonephritis, Membranous | 1 | 2007 | 6 | 0.080 |
Why?
|
| Solutions | 1 | 2007 | 26 | 0.080 |
Why?
|
| Models, Biological | 1 | 2010 | 373 | 0.080 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 2007 | 36 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 546 | 0.080 |
Why?
|
| Equipment Failure | 1 | 2007 | 22 | 0.070 |
Why?
|
| Follow-Up Studies | 3 | 2007 | 2108 | 0.070 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 18 | 0.070 |
Why?
|
| Survival Rate | 1 | 2009 | 795 | 0.070 |
Why?
|
| H(+)-K(+)-Exchanging ATPase | 1 | 2006 | 20 | 0.070 |
Why?
|
| Genetic Markers | 1 | 2006 | 122 | 0.070 |
Why?
|
| Brain Infarction | 1 | 2005 | 10 | 0.070 |
Why?
|
| Phenylbutyrates | 1 | 2005 | 4 | 0.070 |
Why?
|
| Colchicine | 1 | 2005 | 8 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2005 | 18 | 0.070 |
Why?
|
| Guanine | 1 | 2005 | 14 | 0.070 |
Why?
|
| Infection Control | 1 | 2005 | 21 | 0.070 |
Why?
|
| Ischemic Attack, Transient | 1 | 2005 | 46 | 0.070 |
Why?
|
| Adenine | 1 | 2005 | 15 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2005 | 56 | 0.060 |
Why?
|
| Cross Infection | 1 | 2005 | 46 | 0.060 |
Why?
|
| Coronary Angiography | 1 | 2005 | 136 | 0.060 |
Why?
|
| Heparin | 1 | 2005 | 75 | 0.060 |
Why?
|
| Point Mutation | 1 | 2004 | 23 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2004 | 152 | 0.060 |
Why?
|
| Anticoagulants | 1 | 2005 | 120 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 863 | 0.060 |
Why?
|
| Hypertension, Renovascular | 1 | 2004 | 15 | 0.060 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2003 | 3 | 0.060 |
Why?
|
| Base Pairing | 1 | 2003 | 4 | 0.060 |
Why?
|
| Sepsis | 1 | 2005 | 146 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 116 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2005 | 469 | 0.060 |
Why?
|
| Osmolar Concentration | 1 | 2003 | 17 | 0.060 |
Why?
|
| Polyethylenes | 1 | 2003 | 2 | 0.060 |
Why?
|
| Lanthanum | 1 | 2003 | 3 | 0.060 |
Why?
|
| Iron Compounds | 1 | 2003 | 2 | 0.060 |
Why?
|
| Ketoglutaric Acids | 1 | 2003 | 4 | 0.060 |
Why?
|
| Aluminum Compounds | 1 | 2003 | 3 | 0.060 |
Why?
|
| Epoxy Compounds | 1 | 2003 | 5 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 40 | 0.060 |
Why?
|
| Sequence Alignment | 1 | 2003 | 63 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2003 | 82 | 0.060 |
Why?
|
| Calcium Carbonate | 1 | 2003 | 7 | 0.060 |
Why?
|
| Exons | 1 | 2003 | 49 | 0.060 |
Why?
|
| Cardiovascular System | 1 | 2003 | 39 | 0.060 |
Why?
|
| Blood Coagulation Factors | 1 | 2003 | 2 | 0.060 |
Why?
|
| Rhabdomyolysis | 1 | 2002 | 6 | 0.060 |
Why?
|
| Myoglobin | 1 | 2002 | 11 | 0.060 |
Why?
|
| Vascular Diseases | 1 | 2003 | 61 | 0.060 |
Why?
|
| Cysteine | 1 | 2003 | 131 | 0.050 |
Why?
|
| Compartment Syndromes | 1 | 2002 | 38 | 0.050 |
Why?
|
| Early Diagnosis | 2 | 2013 | 61 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2011 | 447 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2019 | 799 | 0.050 |
Why?
|
| Dementia | 1 | 2004 | 234 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 298 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2009 | 1379 | 0.050 |
Why?
|
| Confidence Intervals | 3 | 2005 | 140 | 0.050 |
Why?
|
| Obesity | 1 | 2007 | 1063 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2016 | 532 | 0.050 |
Why?
|
| Ultrasonography | 2 | 2017 | 345 | 0.050 |
Why?
|
| Imidazoline Receptors | 1 | 2019 | 2 | 0.040 |
Why?
|
| Activating Transcription Factor 6 | 1 | 2019 | 3 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 2019 | 4 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 13 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2019 | 13 | 0.040 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2019 | 33 | 0.040 |
Why?
|
| Telomerase | 1 | 2019 | 21 | 0.040 |
Why?
|
| RNA Interference | 1 | 2019 | 76 | 0.040 |
Why?
|
| RNA, Small Interfering | 1 | 2019 | 109 | 0.040 |
Why?
|
| Linear Models | 2 | 2014 | 426 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2019 | 171 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 249 | 0.040 |
Why?
|
| Arthritis, Gouty | 1 | 2018 | 1 | 0.040 |
Why?
|
| Nephrolithiasis | 1 | 2018 | 2 | 0.040 |
Why?
|
| Molecular Structure | 1 | 2018 | 53 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2019 | 281 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2019 | 138 | 0.040 |
Why?
|
| Biopsy, Needle | 1 | 2018 | 89 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 637 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2002 | 494 | 0.040 |
Why?
|
| Podocytes | 1 | 2017 | 20 | 0.040 |
Why?
|
| Survivors | 1 | 2019 | 145 | 0.040 |
Why?
|
| Oxidative Stress | 1 | 2019 | 223 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2018 | 87 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 71 | 0.040 |
Why?
|
| Cell Line | 2 | 2009 | 449 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2019 | 573 | 0.040 |
Why?
|
| Golgi Apparatus | 1 | 2016 | 8 | 0.040 |
Why?
|
| Neutropenia | 1 | 2016 | 23 | 0.040 |
Why?
|
| Homozygote | 1 | 2016 | 57 | 0.040 |
Why?
|
| Canada | 1 | 2016 | 48 | 0.040 |
Why?
|
| Zebrafish | 1 | 2016 | 24 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2016 | 17 | 0.040 |
Why?
|
| Syndrome | 1 | 2016 | 66 | 0.040 |
Why?
|
| Workflow | 1 | 2016 | 20 | 0.040 |
Why?
|
| Mutation, Missense | 1 | 2016 | 48 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2016 | 178 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 280 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2016 | 190 | 0.030 |
Why?
|
| Cystatin C | 2 | 2005 | 28 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 711 | 0.030 |
Why?
|
| Consensus | 1 | 2015 | 68 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 2015 | 62 | 0.030 |
Why?
|
| Blood Pressure | 2 | 2013 | 804 | 0.030 |
Why?
|
| Lung | 1 | 2016 | 233 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2016 | 514 | 0.030 |
Why?
|
| Genotype | 1 | 2016 | 735 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 598 | 0.030 |
Why?
|
| Fibrinogen | 2 | 2004 | 42 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 726 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 2368 | 0.030 |
Why?
|
| Cytosine | 1 | 2013 | 9 | 0.030 |
Why?
|
| C-Reactive Protein | 2 | 2004 | 232 | 0.030 |
Why?
|
| Haplotypes | 1 | 2013 | 220 | 0.030 |
Why?
|
| Comorbidity | 1 | 2013 | 540 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2011 | 225 | 0.020 |
Why?
|
| Atherosclerosis | 2 | 2006 | 693 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2010 | 53 | 0.020 |
Why?
|
| Age of Onset | 1 | 2009 | 95 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2009 | 207 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 191 | 0.020 |
Why?
|
| Risk | 1 | 2007 | 289 | 0.020 |
Why?
|
| Rubidium Radioisotopes | 1 | 2006 | 7 | 0.020 |
Why?
|
| Consensus Sequence | 1 | 2006 | 10 | 0.020 |
Why?
|
| Biotinylation | 1 | 2006 | 10 | 0.020 |
Why?
|
| Alanine | 1 | 2006 | 27 | 0.020 |
Why?
|
| Protein Subunits | 1 | 2006 | 34 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2006 | 97 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 192 | 0.020 |
Why?
|
| Colon | 1 | 2006 | 56 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2006 | 225 | 0.020 |
Why?
|
| Probability | 1 | 2005 | 150 | 0.020 |
Why?
|
| Factor VII | 1 | 2004 | 5 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2004 | 42 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2004 | 55 | 0.020 |
Why?
|
| Dementia, Vascular | 1 | 2004 | 13 | 0.020 |
Why?
|
| Muscles | 1 | 2004 | 53 | 0.020 |
Why?
|
| Chromogranins | 1 | 2003 | 3 | 0.010 |
Why?
|
| Receptors, Erythropoietin | 1 | 2003 | 4 | 0.010 |
Why?
|
| Platelet Activation | 1 | 2003 | 12 | 0.010 |
Why?
|
| Renal Artery Obstruction | 1 | 2004 | 38 | 0.010 |
Why?
|
| Azathioprine | 1 | 2003 | 8 | 0.010 |
Why?
|
| Cyclosporine | 1 | 2003 | 34 | 0.010 |
Why?
|
| Mycophenolic Acid | 1 | 2003 | 28 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 631 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 97 | 0.010 |
Why?
|
| Geriatric Assessment | 1 | 2005 | 355 | 0.010 |
Why?
|
| Intermittent Claudication | 1 | 2003 | 9 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2003 | 44 | 0.010 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2003 | 45 | 0.010 |
Why?
|
| Cadaver | 1 | 2003 | 143 | 0.010 |
Why?
|
| alpha-2-Antiplasmin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Fibrinolysin | 1 | 2003 | 2 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 71 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2003 | 17 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2003 | 87 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 248 | 0.010 |
Why?
|
| Nerve Tissue Proteins | 1 | 2003 | 118 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 273 | 0.010 |
Why?
|
| Pressure | 1 | 2002 | 54 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 145 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2003 | 149 | 0.010 |
Why?
|
| Hindlimb | 1 | 2002 | 57 | 0.010 |
Why?
|
| Rabbits | 1 | 2002 | 185 | 0.010 |
Why?
|
| Korea | 1 | 2002 | 3 | 0.010 |
Why?
|
| Hematocrit | 1 | 2002 | 23 | 0.010 |
Why?
|
| Age Distribution | 1 | 2002 | 198 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2003 | 225 | 0.010 |
Why?
|
| Cholesterol, HDL | 1 | 2002 | 165 | 0.010 |
Why?
|
| Cholesterol, LDL | 1 | 2002 | 157 | 0.010 |
Why?
|
| Nutritional Status | 1 | 2002 | 68 | 0.010 |
Why?
|
| Iron | 1 | 2002 | 113 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 312 | 0.010 |
Why?
|
| Stroke | 1 | 2005 | 545 | 0.010 |
Why?
|
| Body Weight | 1 | 2002 | 290 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2005 | 1218 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 507 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 980 | 0.010 |
Why?
|